Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Strides Shasun to...

    Strides Shasun to acquire Perrigo API India for Rs 100 cr

    Written by savita thakur thakur Published On 2016-12-12T12:35:55+05:30  |  Updated On 12 Dec 2016 12:35 PM IST
    Strides Shasun to acquire Perrigo API India for Rs 100 cr

    Drug firm Strides Shasun said it has inked pacts to acquire Perrigo API India for Rs 100 crore.


    The company has signed "definitive agreements to acquire the entire shareholding in Perrigo API India Pvt Ltd (Perrigo API India) for Rs 1,000 million," Strides Shasun said in a BSE filing.



    The transaction is expected to be closed by December 31, 2016, it added.

    Commenting on the development, Strides Shasun Group CEO Shashank Sinha said: "With this acquisition, we bring into our fold a manufacturing facility designed to handle multipurpose small batch productions and accelerates our time to market."

    This augurs well for the Strides' stated strategy of building a backward integrated portfolio of niche and small volume products for the regulated markets, he added.

    Perrigo API India's USFDA approved API facility at Ambernath in Maharashtra is to be used for "captive consumption and will augment the company's resources to handle high velocity of new product development and commercial launches in the formulations portfolio," Strides Shasun said.

    As per the agreements, Perrigo parent or affiliates will continue to source few products from the facility under a long term supply agreement, it added.




    approvalPerrigo API IndiaShashank SinhaShasun Group CEOStrides ShasunUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok